The higher the dividend yield, the more investors will worry. Pfizer (Pfe +0.30%) Boasts a forward dividend yield of 6.5%, the highest yield among large-cap healthcare stocks. Not surprisingly, some have viewed Pfizer as a yield net.
Although Pfizer’s dividend yield may look great to some investors, that no longer has to be the case. The company provided its first quarterly update on Tuesday, May 5, 2026. And I think management silenced the skeptics.
Image Source: Getty Images.
Relief news from Pfizer for income investors
Pfizer CEO Albert Bourla addressed any doubts about the drugmaker’s commitment to its dividend in the Q1 call, saying, “We intend to maintain and grow our dividend over time as we continue to deliver and create long-term value.” CFO David Denton reinforced this message, saying that Pfizer’s strategy includes “maintaining and growing our dividend over time.”
Were they just meaningless words? I don’t think so. One reason is that Pfizer now has greater cash flow visibility due to the legal settlement related to the Vindamax patent infringement and the Belgian court’s ruling on Comirnaty contracts with EU countries. These two developments have significantly improved Pfizer’s ability to support its dividend.
Pfizer has made large acquisitions in the past that have resulted in dividend cuts. Can history repeat itself? Bourla was asked about this possibility in the first-quarter earnings call. He responded that Pfizer will always look for mergers and acquisitions opportunities, but the company is not planning a large-scale merger. Bourla said the disruption in the mega merger will negatively impact the organization’s implementation of artificial intelligence (AI) transformation.
today’s change
(0.30%) $0.08
current price
$26.53
key data points
market cap
$151B
day limit
$26.21 -$26.68
52wk range
$21.97 -$28.75
volume
80K
average volume
39m
gross margin
66.23%
dividend yield
6.48%
The near future looks good for Pfizer. The company generated operating cash flow in Q1 more than needed to cover the dividend. Pfizer beat Wall Street expectations with its Q1 results. Denton indicated the drugmaker probably would have raised its guidance if it weren’t for its “philosophy of not really making adjustments in Q1.”
The long term also looks bright. Management is now “more confident” that the company will deliver high single-digit revenue growth as early as 2029. Pfizer has promising pipeline programs, particularly in its development of cancer and obesity treatments.
A yield trap? No way.
If Pfizer’s Q1 update had given investors reason to worry about weak cash flow, legal questions and growth-related uncertainty, skeptics who view the stock as a yield trap would have had some ammunition. However, this was not the case at all. Instead, we heard Pfizer discuss strong cash flow generation, major legal wins, and growing confidence in solid growth in the coming years.
Pfizer’s dividend appears to be more secure than previously thought ahead of its first-quarter results. The 6.5% yield isn’t too good to be true. what’s here Is Fact: Pfizer is one of the most attractive dividend stock Now on the market.